Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment
The Journal of Clinical Endocrinology & Metabolism · 17.03.2026 · 111 (4) · e1050-e1063
DOI: 10.1210/clinem/dgaf579 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 23.10.2025. Verfasst von Beverly M K Biller und 17 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Acromegaly, Receptors, Somatostatin. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Crinetics Pharmaceuticals, Inc.
Abstract (Originalsprache)
Context
Paltusotine is a nonpeptide, selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly.
Objective
To evaluate efficacy and safety of paltusotine in patients with biochemically uncontrolled acromegaly not currently receiving medical therapy.
Methods
In this phase 3, randomized, double-blind, placebo-controlled trial, adults with medically untreated acromegaly at randomization (stratum 1: medication-naïve or off acromegaly medications ≥4 months [IGF-I ≥ 1.3 × upper limit of normal {ULN}]; stratum 2: controlled on a somatostatin receptor ligand and underwent washout [IGF-I increase ≥30% to ≥1.1 × ULN]) received paltusotine or placebo for 24 weeks.
Results
A total of 111 patients (stratum 1, n = 82; stratum 2, n = 29) enrolled (paltusotine, n = 54; placebo, n = 57). The primary endpoint of IGF-I normalization at 24 weeks was met in 55.6% of paltusotine-treated patients vs 5.3% for placebo (odds ratio [OR]: 42.81; 95% CI, 8.44-455.82; P < .0001), with superiority to placebo in both strata. Paltusotine treatment decreased IGF-I in 92.6% of patients within the first 4 weeks. All secondary endpoints were met: mean (±SE) change in IGF-I of -0.82 ± 0.08×ULN with paltusotine vs 0.09 ± 0.08×ULN with placebo (P < .0001); IGF-I < 1.3×ULN in 66.7% vs 14.0% of patients (OR: 18.32; 95% CI, 5.64-79.16; P < .0001); GH (5-sample mean) < 1.0 ng/mL in 57.4% vs 17.5% (OR: 7.59; 95% CI, 2.78-23.48; P < .0001); mean (±SE) change in Acromegaly Symptom Diary score of -2.7 ± 1.4 vs 2.8 ± 1.4 (P = .004). Most adverse events were acromegaly symptoms or mild, transitory gastrointestinal effects characteristic of somatostatin receptor ligands (eg, diarrhea, abdominal pain). Pituitary tumor volume was stable or reduced in paltusotine-treated patients.
Conclusion
IGF-I normalized in significantly more patients with uncontrolled acromegaly treated with paltusotine vs placebo. Paltusotine was associated with rapid, sustained IGF-I reduction, significant symptom improvement and stable or reduced pituitary tumor size and was well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA 02114, USA.
- Crinetics Pharmaceuticals, Inc, San Diego, CA 92121, USA.
- Department of Endocrinology, Medical University-Sofia, USHATE "Acad. Ivan Penchev", Sofia 1431, Bulgaria.
- Department of Internal Medicine, Endocrine Division (SEMPR), Federal University of Paraná, Curitiba 80030-110, Brazil.
- Neuroendocrine Unit, Division of Endocrinology and Metabolism, Clinics Hospital, University of São Paulo Medical School, São Paulo 01246-903, Brazil.
- 2nd Department of Internal Medicine, Division of Endocrinology, Central Hospital of Northern Pest-Military Hospital, Budapest 1134, Hungary.
ORCID-Profile: Beverly M K Biller, Raquel S Jallad, Maria Fleseriu, Martin Bidlingmaier, Alan Krasner
Förderung
- Crinetics Pharmaceuticals, Inc
Zitieren
APA
Biller, B. M. K., Casagrande, A., Elenkova, A., Boguszewski, C. L., Jallad, R. S., Hu, B., Hubina, E., Fazeli, P. K., Fleseriu, M., Snyder, P. J., Strasburger, C. J., Bidlingmaier, M., Zhao, Y., Soares, B., Trainer, P. J., Struthers, R. S., Krasner, A., & Gadelha, M. R. (2026). Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment. The Journal of Clinical Endocrinology & Metabolism, 111(4), e1050-e1063. https://doi.org/10.1210/clinem/dgaf579
Vancouver
Biller BMK, Casagrande A, Elenkova A, Boguszewski CL, Jallad RS, Hu B, et al. Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment. The Journal of Clinical Endocrinology & Metabolism. 2026;111(4):e1050-e1063. doi:10.1210/clinem/dgaf579
BibTeX
@article{Biller2026,
author = {Biller, Beverly M K and Casagrande, Alessandra and Elenkova, Atanaska and Boguszewski, Cesar L and Jallad, Raquel S and Hu, Beibei and Hubina, Erika and Fazeli, Pouneh K and Fleseriu, Maria and Snyder, Peter J and Strasburger, Christian J and Bidlingmaier, Martin and Zhao, Yining and Soares, Beatriz and Trainer, Peter J and Struthers, R Scott and Krasner, Alan and Gadelha, Mônica R},
title = {Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {4},
pages = {e1050--e1063},
doi = {10.1210/clinem/dgaf579}
}
EUVIMED